Anticoagulant treatment of patients (pts) with cancer associated thromboembolism (CAT) in Germany: Real world data from a 4 million people sample generated by insurance captured data

Albrecht Kretzschmar(Roche (Switzerland)), Hanno Riess(Charité - Universitätsmedizin Berlin), Andreas Heinken(Bavarian Nordic (Germany)), Martin M May

Annals of Oncology

October 1, 2018

10.1093/annonc/mdy297.023

Cited by 0

Related Papers

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

|European Journal of Cancer|2011|615

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

|Annals of Oncology|2009|534

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group

|Journal of Clinical Oncology|2007|281

Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial

|Annals of Oncology|2005|223

Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial

|Journal of Clinical Oncology|2023|212